ArticleFrontiers in pharmacology2025
Automated fluorine-18 radiolabeling via an alkyne-azide cycloaddition reaction on a dual peptide-functionalized liposome surface for
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peptide-mimetics derived from leucyl-tRNA synthetase are potential agents for the therapy of mt-tRNA related diseases.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Labeled nanoparticles can be monitored in the body using positron emission tomography (PET) imaging, providing real-time insights into their pharmacokinetics and biodistribution. In the present work, liposomes are labeled with the radionuclide fluorine-18, exploiting a "surface radiolabeling" approach. Methods: Two alkyne-dioleoylphosphatidylethanolamine (DOPE) constructs are embedded within the bulk of the liposome bilayer, which is composed of cholesterol (Ch) and sphingomyelin (SM), and radiolabeling is performed via either a copper(I)-catalyzed cycloaddition "click" reaction (CuAAC) or a cyclooctyne-driven copper-free "click" reaction (CyOctC) modality, using a suitable fluorine-18 labeled azide, obtaining good results in terms of yield, purity, stability, and automation of the entire radiosynthesis process. In addition, radiolabeling is also performed on liposome formulations functionalized with 1) a peptide derived from the receptor-binding domain of apolipoprotein E (mApoE) and 2) a metalloproteinase (MMP)-sensitive lipopeptide (MSLP). The in vivo uptake of these liposomes is evaluated in an orthotopic glioma mouse model (Gli36ΔEGFR cell line) using PET/computed tomography (CT). Results and discussion: The results demonstrate a higher tumor/background ratio, a faster clearance rate, and a lower uptake in healthy brain tissue and peripheral regions for mApoE- and MSLP-functionalized liposomes than for non-functionalized liposomes, prompting further characterization. On the contrary, radiolabeled liposome uptake is higher in the majority of peripheral organs for non-functionalized liposomes. Hence, fluorine-18-labeled liposomes can be reliably used for in vivo PET tracking of multifunctionalized nanoparticles, enabling effective investigation of their potential as drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.